The DOI matches its Crossref record; 91 of the 93 references it cites were found in a registry or an index.
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
Open accessAbstract
All cancers originate from a single cell that starts to behave abnormally due to the acquired somatic mutations in its genome. Until recently, the knowledge of the mutational processes that cause these somatic mutations has been very limited. Recent advances in sequencing technologies and the development of novel mathematical approaches have allowed deciphering the patterns of somatic mutations caused by different mutational processes. Here, we summarize our current understanding of mutational patterns and mutational signatures in light of both the somatic cell paradigm of cancer research and the recent developments in the field of cancer genomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that pol h may be mutagenic only in some types of blood cancer, consistent with the results of previous studies 39 .”
From DNA polymerase η mutational signatures are found in a variety of different types of cancer (2018) · cites this paper as [39]
In the citing paper
“The excess of pol h mutable motifs in chronic lymphocytic leukemia and GCB lymphomas that we detected in our work is consistent with the studies of Alexandrov et al. 39”
From DNA polymerase η mutational signatures are found in a variety of different types of cancer (2018) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Learning the parts of objects by non-negative matrix factorization
Lee, D. D., & Seung, H. S. (1999) · Nature · doi:10.1038/44565 · Cited by 14,137
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
Self-citationComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Flagged first, then by citations
2 of the 93 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The repertoire of mutational signatures in human cancer
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature · doi:10.1038/s41586-020-1943-3 · Cited by 3,496
Self-citationPan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Self-citationPan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
“The distribution of tumor mutational signatures across the study cohorts largely reflected recognized cancer subtype–dependent determinants of mutagenesis (17) (table S3 and fig.”
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Self-citationEndogenous DNA damage as a source of genomic instability in cancer
Tubbs, A., & Nussenzweig, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.002 · Cited by 1,452
Whole-genome landscapes of major melanoma subtypes
Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,495
Self-citationMutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100
Self-citationClock-like mutational processes in human somatic cells
Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik‐Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,065
Self-citationThe head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A.-T., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 785
“Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.”
MethodInfluentialSubstantial contribution of extrinsic risk factors to cancer development
Wu, S., Powers, S., Zhu, W., & Hannun, Y. A. (2015) · Nature · doi:10.1038/nature16166 · Cited by 691
Advancements in Next-Generation Sequencing
Levy, S., & Myers, R. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022413 · Cited by 630
Design and Analysis of Single-Cell Sequencing Experiments
Grün, D., & van Oudenaarden, A. (2015) · Cell · doi:10.1016/j.cell.2015.10.039 · Cited by 536
“During each cell division, DNA replication errors can escape the DNA repair machinery with a small probability and can lead to so-called somaticmutations, which can give rise to cancer (Alexandrov and Stratton, 2014) and other diseases (Biesecker and Spinner, 2013).”
BackgroundTherapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
The Repertoire of Mutational Signatures in Human CancerPreprint
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Ng, A. W. T., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/322859 · Cited by 529
Self-citationSignatures of copy number alterations in human cancer
Steele, C. D., Abbasi, A., Islam, S. M. A., Bowes, A. L., Khandekar, A., Haase, K., Hames-Fathi, S., Ajayi, D., Verfaillie, A., Dhami, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04738-6 · Cited by 487
Self-citationEvaluating intrinsic and non-intrinsic cancer risk factors
Wu, S., Zhu, W., Thompson, P. A., & Hannun, Y. A. (2018) · Nature Communications · doi:10.1038/s41467-018-05467-z · Cited by 473
Accelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Shrestha-Bhattarai, T., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S. M., Kandoth, C., Penson, A. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 413
“We analyzed each of the 32 organ sites independently as well as the full cohort (pan-cancer) to enhance the probability of identifying hotspots that occur rarely in multiple organ types of different mutational burdens and processes (9).”
Ng, A. W. T., Poon, S. L., Huang, M. N., Lim, J. Q., Boot, A., Yu, W., Suzuki, Y., Thangaraju, S., Ng, C. C. Y., Tan, P. B. O., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6446 · Cited by 377
George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., Maas, L., Müller, C., Dahmen, I., Delhomme, T. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03099-x · Cited by 381
Self-citationTracking the origins and drivers of subclonal metastatic expansion in prostate cancer
Hong, M. K. H., Macintyre, G., Wedge, D. C., Loo, P. V., Patel, K., Lunke, S., Alexandrov, L. B., Sloggett, C., Cmero, M., Marass, F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7605 · Cited by 367
Self-citationChemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 372
Rotte, A., Jin, J., & Lemaire, V. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 352
Epidemiology and Risk Factors for Kidney Cancer
Scelo, G., & Larose, T. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.1905 · Cited by 329
“Tumor genomics promises to causally identify individual tumors via mutational signatures that are specific to underlying exo- or endogenic causes.(69,83) Finally, improvements along the diagnostic pathway can lead to earlier diagnosis and better prognosis.”
BackgroundThe evolution of tumour phylogenetics: principles and practice
Schwartz, R. S., & Schäffer, A. A. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.170 · Cited by 329
Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Schulze, K., Nault, J., & Villanueva, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.035 · Cited by 327
SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events
Bergstrom, E. N., Huang, M. N., Mahto, U., Barnes, M. D., Stratton, M. R., Rozen, S., & Alexandrov, L. B. (2019) · BMC Genomics · doi:10.1186/s12864-019-6041-2 · Cited by 305
Self-citationInman, G. J., Wang, J., Nagano, A., Alexandrov, L. B., Purdie, K. J., Taylor, R. G., Sherwood, V., Thomson, J., Hogan, S., Spender, L. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06027-1 · Cited by 310
Self-citationNK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268
“However, tumors may evade the CD8+ T cell response via selective or complete loss of major histocompatibility complex (MHC) class I expression (5–7) or because they express few or no neoantigens (8) and may consequently be refractory to CD8+ T cell–dependent therapies.”
BackgroundTEIXEIRA, V. H., Pipinikas, C., Pennycuick, A., Lee-Six, H., Chandrasekharan, D. P., Beane, J., Morris, T. J., Karpathakis, A., Feber, A., Breeze, C. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0323-0 · Cited by 255
Lagging-strand replication shapes the mutational landscape of the genome
Reijns, M. A. M., Kemp, H., Ding, J., Marion de Procé, S., Jackson, A. P., & Taylor, M. S. (2015) · Nature · doi:10.1038/nature14183 · Cited by 241
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis
Taniue, K., & Akimitsu, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020632 · Cited by 221
“Multiple studies have shown that somatic mutations in protein-coding genes are the driving force of cancer development [5,6].”
BackgroundGladyshev, V. N., Kritchevsky, S. B., Clarke, S. G., Cuervo, A. M., Fiehn, O., de Magalhães, J. P., Mau, T., Maes, M., Moritz, R. L., Niedernhofer, L. J., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00150-3 · Cited by 222
Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?
Yarmolinsky, J., Wade, K. H., Richmond, R. C., Langdon, R., Bull, C. J., Tilling, K. M., Relton, C. L., Lewis, S. J., Smith, G. D., & Martin, R. M. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-1177 · Cited by 189
“Of the mutational signatures identified across cancer types, a putative cause has been proposed for approximately half (158); MR may offer particular promise in helping to identify the etiology of other mutational signatures identified (160).”
BackgroundFrailty in childhood cancer survivors
Ness, K. K., Armstrong, G. T., Kundu, M., Wilson, C. L., Tchkonia, T., & Kirkland, J. L. (2015) · Cancer · doi:10.1002/cncr.29211 · Cited by 188
Clusters of Multiple Mutations: Incidence and Molecular Mechanisms
Chan, K., & Gordenin, D. A. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054714 · Cited by 191
“Several prominent mutation signatures consisting of mutated nucleotide and immediate (1–2 nucleotides) surrounding context (reviewed in (5; 10; 53; 94; 106)) have been identified.”
BackgroundPathway-driven discovery of epilepsy genes
Noebels, J. L. (2015) · Nature Neuroscience · doi:10.1038/nn.3933 · Cited by 191
A mutational signature in gastric cancer suggests therapeutic strategies
Alexandrov, L. B., Nik‐Zainal, S., Siu, H. C., Leung, S. Y., & Stratton, M. R. (2015) · Nature Communications · doi:10.1038/ncomms9683 · Cited by 178
Self-citationTRIP13 regulates DNA repair pathway choice through REV7 conformational change
Clairmont, C. S., Sarangi, P., Ponnienselvan, K., Galli, L. D., Csete, I., Moreau, L. A., Adelmant, G., Chowdhury, D., Marto, J. A., & D’Andrea, A. D. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0442-y · Cited by 161
Kolinjivadi, A. M., Sannino, V., Antoni, A. D., Técher, H., Baldi, G., & Costanzo, V. (2017) · FEBS Letters · doi:10.1002/1873-3468.12556 · Cited by 155
Epidemiology and Molecular Biology of Head and Neck Cancer
Jou, A., & Heß, J. (2017) · Oncology Research and Treatment · doi:10.1159/000477127 · Cited by 154
Molecular mechanisms of the preventable causes of cancer in the United StatesPreprint
Golemis, E. A., Scheet, P. A., Beck, T. N., Scolnick, E. M., Hunter, D. J., Hawk, E. T., & Hopkins, N. H. (2018) · Genes & Development · doi:10.1101/gad.314849.118 · Cited by 164
“…generated by genomic, transcriptomic, and proteomic analysis (Cote et al. 2016); allow comparisonwith functional testing in animal models (Rudel et al. 2014); and can be benchmarked to characteristic profiles generated for specific mutagens (Alexandrov and Stratton 2014; Nik-Zainal et al. 2015).”
BackgroundLópez, C., Kleinheinz, K., Aukema, S., Rohde, M., Bernhart, S. H., Hübschmann, D., Wagener, R., Toprak, U. H., Raimondi, F., Kreuz, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08578-3 · Cited by 151
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 149
““Genomic scars” (mutational signatures and alterations in genome structure) Genomic scars represent accumulated patterns of DNA damage and repair identified by genomic profiling (33-35).”
BackgroundAPOBEC3A catalyzes mutation and drives carcinogenesis in vivo
Law, E. K., Levin-Klein, R., Jarvis, M. C., Kim, H., Argyris, P. P., Carpenter, M. A., Starrett, G. J., Temiz, N. A., Larson, L. K., Durfee, C. C., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200261 · Cited by 139
“Knowledge of the intrinsic (bio)chemical preferences of mutagens together with more recent advances in DNA sequencing and bioinformatics have made it possible to break complex mutation landscapes into simpler individual components [reviewed by (Alexandrov and Stratton, 2014; Helleday et al., 2014; Roberts and Gordenin…”
BackgroundCancer prevention as part of precision medicine: ‘plenty to be done’
Stewart, B. W., Bray, F., Forman, D., Ohgaki, H., Straif, K., Ullrich, A., & Wild, C. P. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv166 · Cited by 148
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 138
Precision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 138
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 144
Natrajan, R., Sailem, H., Mardakheh, F. K., Arias-García, M., Tape, C. J., Dowsett, M., Bakal, C., & Yuan, Y. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001961 · Cited by 134
Molecular subtypes and precision treatment of triple-negative breast cancer
Zhao, S., Zuo, W., Shao, Z., & Jiang, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.194 · Cited by 140
“In the past decade, large-scale sequencing studies have revealed many mutational signatures across the spectrum of human cancer types (19-21).”
BackgroundNext-Generation Sequencing StrategiesPreprint
Levy, S., & Boone, B. E. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025791 · Cited by 140
“…applications, both genome-wide and targeted, are revealing complex mutational signatures associated with different types of cancers that are now driving both research and therapeutic decisions (Nik-Zainal et al. 2012; Alexandrov et al. 2013a,b; Alexandrov and Stratton 2014; Helleday et al. 2014).”
BackgroundDeciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy
Gilson, P., Merlin, J., & Harlé, A. (2022) · Cancers · doi:10.3390/cancers14061384 · Cited by 138
Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumorsPreprint
Huang, M.-N., Yu, W., Teoh, W. W., Ardin, M., Jusakul, A., Ng, A., Boot, A., Abedi-Ardekani, B., Villar, S., Myint, S. S., et al. (2017) · bioRxiv · doi:10.1101/gr.220038.116 · Cited by 111
“…in molecular cancer epidemiology because they bear witness to mutagenic exposures and because they illuminate endogenous mutagenic processes and mechanisms of DNA damage and repair (Alexandrov and Stratton 2014; Helleday et al. 2014; Poon et al. 2014; Nik-Zainal et al. 2015; Hollstein et al. 2016).”
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Self-citationBeal, M. A., Yauk, C. L., & Marchetti, F. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.04.001 · Cited by 129
Starrett, G. J., Marcelus, C., Cantalupo, P. G., Katz, J. P., Cheng, J., Akagi, K., Thakuria, M., Rabinowits, G., Wang, L. C., Symer, D. E., et al. (2017) · mBio · doi:10.1128/mbio.02079-16 · Cited by 126
Why is pancreatic cancer so deadly? The pathologist's view
Hruban, R. H., Gaida, M. M., Thompson, E., Hong, S., Noë, M., Brosens, L. A., Jongepier, M., Offerhaus, G. J. A., & Wood, L. D. (2019) · The Journal of Pathology · doi:10.1002/path.5260 · Cited by 115
“Pancreatic cancers have relatively low mutational burdens, with an average of one mutation per megabase compared with over ten mutations per megabase in melanoma and just under ten mutations per megabase in non-small cell lung cancer (NSCLC) [117].”
BackgroundsigneR: an empirical Bayesian approach to mutational signature discovery
Rosales, R., Drummond, R. D., Valieris, R., Dias‐Neto, E., & da Silva, I. T. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw572 · Cited by 112
“The actual identification of the underlying mutational processes is central to an understanding of cancer origin and evolution (Alexandrov, 2013; Alexandrov and Stratton, 2014; Helleday et al., 2014; Roberts and Gordenin, 2014). Most somatic mutations comprise single base substitutions, insertions and deletions, rearr…”
BackgroundInfluentialAnadon, C. M., Guil, S., Simó‐Riudalbas, L., Moutinho, C., Setién, F., Martínez‐Cardús, A., Morán, S., Villanueva, A., Calaf, M., Vidal, A., et al. (2015) · Oncogene · doi:10.1038/onc.2015.469 · Cited by 112
“Analysis of the spectrum of mutations has implicated APOBEC-mediated editing in many cancers 8 and the contribution of AID to lymphomagenesis is well established 9 .”
Mutation signatures implicate aristolochic acid in bladder cancer development
Poon, S. L., Huang, M. N., Choo, Y., McPherson, J. R., Yu, W., Heng, H. L., Gan, A., Myint, S. S., Siew, E. Y., Ler, L. D., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0161-3 · Cited by 106
“Indeed, inexpensive next-generation sequencing provides a new molecular epidemiological tool for inferring environmental exposures and endogenous mutational processes that occurred prior to and during oncogenesis [11-17].”
BackgroundAnalysis of cancer genomes reveals basic features of human aging and its role in cancer development
Podolskiy, D. I., Lobanov, A. V., Kryukov, G. V., & Gladyshev, V. N. (2016) · Nature Communications · doi:10.1038/ncomms12157 · Cited by 100
“To identify which types of mutations are most strongly accumulated with age, we performed the analysis of mutational patterns in available TCGA samples 12,25,26 by applying the method of proper orthogonal decomposition to the TCGA data sets for both developed and early stage cancers (Fig.”
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 101
Detecting presence of mutational signatures in cancer with confidence
Huang, X., Wójtowicz, D., & Przytycka, T. M. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx604 · Cited by 99
“Especially noisy are signatures 3, 5 and 8.”
BackgroundMaharjan, R. P., & Ferenci, T. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001477 · Cited by 98
sigfit: flexible Bayesian inference of mutational signaturesPreprint
Gori, K. C., & Baez‐Ortega, A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/372896 · Cited by 91
“) A vector of mutation counts or mutation probabilities across these 96 mutation categories is known as a mutational catalogue, or spectrum (1, 3).”
BackgroundInfluentialBreast Cancer Organoids Model Patient-Specific Response to Drug Treatment
Campaner, E., Zannini, A., Santorsola, M., Bonazza, D., Bottin, C., Cancila, V., Tripodo, C., Bortul, M., Zanconati, F., Schoeftner, S., et al. (2020) · Cancers · doi:10.3390/cancers12123869 · Cited by 97
APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma
Cannataro, V. L., Gaffney, S. G., Sasaki, T., Issaeva, N., Grewal, N., Grandis, J. R., Yarbrough, W. G., Burtness, B. A., Anderson, K. S., & Townsend, J. P. (2019) · Oncogene · doi:10.1038/s41388-018-0657-6 · Cited by 93
“Patterns within the burden of mutations in a cancer provide insight into the mechanism of mutation (27).”
BackgroundWhole-Genome Sequencing in CancerPreprint
Stutheit-Zhao, E. Y., Jones, M. R., & Jones, S. J. M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034579 · Cited by 93
“…how such approaches fill gaps in our understanding of the genome between the exons and expand the known repertoire of biological mechanisms underlying tumorigenesis with potential clinical use (Alexandrov et al. 2013b; Alexandrov and Stratton 2014; Davies et al. 2017; Zolkind and Uppaluri 2017).”
BackgroundBase changes in tumour DNA have the power to reveal the causes and evolution of cancer
Hollstein, M. C., Alexandrov, L. B., Wild, C. P., Ardin, M., & Zavadil, J. (2016) · Oncogene · doi:10.1038/onc.2016.192 · Cited by 85
Self-citationSignatures of TOP1 transcription-associated mutagenesis in cancer and germline
Reijns, M. A. M., Parry, D. A., Williams, T., Nadeu, F., Hindshaw, R. L., Rios-Szwed, D. O., Nicholson, M. D., Carroll, P., Boyle, S., Royo, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04403-y · Cited by 83
Ultraviolet radiation-mediated development of cutaneous melanoma: An update
Emri, G., Paragh, G., Tósaki, Á., Janka, E. A., Kollár, S., Hegedűs, C., Gellén, E., Horkay, I., Koncz, G., & Remenyik, É. (2018) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2018.06.005 · Cited by 87
UVA Radiation, DNA Damage, and Melanoma
Jin, S., Padron, F., & Pfeifer, G. P. (2022) · ACS Omega · doi:10.1021/acsomega.2c04424 · Cited by 87
Exploring background mutational processes to decipher cancer genetic heterogeneity
Goncearenco, A., Rager, S. L., Li, M., Sang, Q. A., Rogozin, I. B., & Panchenko, A. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx367 · Cited by 76
Challenges of deciphering gastric cancer heterogeneity
Hudler, P. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10510 · Cited by 80
Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors
Asiedu, M. K., Thomas, C. F., Dong, J., Schulte, S. C., Khadka, P., Sun, Z., Kosari, F., Jen, J., Molina, J. R., Vasmatzis, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0252 · Cited by 82
Cao, Y. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0188-9 · Cited by 78
“Molecular studies have identified enormous amount of somatic gene mutations, when considering around 30,000 somatic mutations in TP53 alone [2], that could be related to these malignant properties in cancer cells.”
BackgroundPhillips, D. H. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.003 · Cited by 78
“Around a third of the 30 signatures have been attributed to endogenous mutagenic processes, such as the activity of the APOBEC family of deaminases and deamination of 5-methylcytosine, deficiencies in DNA repair processes, including mismatch repair and homologous recombination, or defective DNA polymerases [17].”
BackgroundMeasuring Clonal Evolution in Cancer with Genomics
Williams, M. J., Sottoriva, A., & Graham, T. A. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021712 · Cited by 83
Pathogenesis of hepatocellular carcinoma according to aetiology
Nault, J. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.08.006 · Cited by 75
Ritch, E. J., Fu, S. Y. F., Herberts, C., Wang, G., Warner, E. W., Schönlau, E., Taavitsainen, S., Murtha, A. J., Vandekerkhove, G. R., Beja, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1623 · Cited by 77
“WES identifies MMRd etiology MMRd results in a distinctive pattern of genomic scarring that cannot be easily discerned from targeted sequencing data (36).”
BackgroundRutledge, S. M., & Asgharpour, A. (2020) · PubMed Central · Cited by 72
Nagahashi, M., Wakai, T., Shimada, Y., Ichikawa, H., Kameyama, H., Kobayashi, T., Sakata, J., Yagi, R., Sato, N., Kitagawa, Y., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0387-8 · Cited by 75
“We further explored the utility of CGS to provide clinically meaningful patterns of mutational signatures [34] from the J-CRC cohort (Fig.”
BackgroundMethodInfluentialHodel, K. P., Sun, M. J. S., Ungerleider, N., Park, V. S., Williams, L. G., Bauer, D. L., Immethun, V. E., Wang, J., Suo, Z., Lu, H., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.012 · Cited by 70
“Whole-genome and -exome sequencing coupled with computational mutation signature extraction have proven incredibly powerful tools to help define global mutation patterns and tumor etiologies in cancer patients (Alexandrov et al., 2013a; Alexandrov et al., 2013b; Alexandrov and Stratton, 2014; Helleday et al., 2014; Ni…”
BackgroundStakeholders’ perspectives on biobank-based genomic research: systematic review of the literature
Husedzinovic, A., Ose, D. J., Schickhardt, C., Fröhling, S., & Winkler, E. C. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.27 · Cited by 68
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Hoefsmit, E. P., Rozeman, E. A., Van, T. M., Dimitriadis, P., Krijgsman, O., Conway, J. W., da Silva, I. P., van der Wal, J. E., Ketelaars, S. L. C., Bresser, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001501 · Cited by 69
Human Germline Mutation and the Erratic Evolutionary Clock
Moorjani, P., Gao, Z., & Przeworski, M. (2016) · PLoS Biology · doi:10.1371/journal.pbio.2000744 · Cited by 68
“with age, depending on their source and repair rates over ontogenesis [31,51].”
BackgroundMutational signature SBS8 predominantly arises due to late replication errors in cancer
Singh, V. K., Rastogi, A., Hu, X., Wang, Y., & De, S. (2020) · Communications Biology · doi:10.1038/s42003-020-01119-5 · Cited by 65
Sato, K., Kawazu, M., Yamamoto, Y., Ueno, T., Kojima, S., Nagae, G., Abe, H., Soda, M., Oga, T., Kohsaka, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1574 · Cited by 65
POLE proofreading defects: Contributions to mutagenesis and cancer
Park, V. S., & Pursell, Z. F. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.02.007 · Cited by 63
Proteogenomic characterization of MiT family translocation renal cell carcinoma
Qu, Y., Wu, X., Anwaier, A., Feng, J., Xu, W., Pei, X., Zhu, Y., Liu, Y., Bai, L., Yang, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34460-w · Cited by 62
Irregularities in genetic variation and mutation rates with environmental stresses
Ferenci, T. (2019) · Environmental Microbiology · doi:10.1111/1462-2920.14822 · Cited by 64
The end of the genetic paradigm of cancer
Huang, S., Soto, A. M., & Sonnenschein, C. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003052 · Cited by 68
“[8] The core of the genetic paradigm: Somatic Darwinian evolution To revisit the role of mutations in carcinogenesis, we need to recall a central corollary of the cancer genetics paradigm that links somatic mutations to the cancer phenotype and cancer progression: namely, the idea of somatic…”
The African Esophageal Cancer Consortium: A Call to Action
Loon, K. V., Mwachiro, M., Abnet, C. C., Akoko, L., Assefa, M., Burgert, S. L., Chasimpha, S., Dzamalala, C. P., Fleischer, D. E., Gopal, S., et al. (2018) · Journal of Global Oncology · doi:10.1200/jgo.17.00163 · Cited by 64
Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice
Aden, K., Bartsch, K., Dahl, J. M., Reijns, M. A. M., Esser, D., Sheibani‐Tezerji, R., Sinha, A. N., Wottawa, F., Ito, G., Mishra, N., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.047 · Cited by 62
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma
Huang, Y. F., Wang, J., Jia, P., Li, X., Pei, G., Wang, C., Fang, X., Zhao, Z., Cai, Z., Yi, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09241-7 · Cited by 66
Uzilov, A. V., Taik, P., Cheesman, K. C., Javanmard, P., Ying, K., Roehnelt, A., Wang, H., Fink, M. Y., Lau, C. Y., Moe, A. S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa853 · Cited by 66
Gatenby, R. A., & Brown, J. S. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.005 · Cited by 62
“This is, in fact, observed in normal epithelial cells [8,33,34].”
Brain Somatic Mutation in Aging and Alzheimer's Disease
Miller, M. B., Reed, H., & Walsh, C. A. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-121520-081242 · Cited by 57
“Analysis of the specific DNA base changes and their trinucleotide contexts can identify signatures that reflect the origin of those somatic mutations (3, 4, 65).”
BackgroundHomeostasis Back and Forth: An Ecoevolutionary Perspective of CancerPreprint
Basanta, D., & Anderson, A. R. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028332 · Cited by 58
Metadata
- Authors
- Alexandrov, L. B., & Stratton, M. R.
- Affiliations
- Wellcome Sanger Institute (GB)
- Corresponding author
- Alexandrov, Ludmil B
- Venue
- Current Opinion in Genetics & Development
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 24
- Pages
- 52-60
- ISSN
- 0959-437X (ISSN-L)
- PMC
- PMC3990474
- OpenAlex
- W1973702005
- Cited by
- 488
- References
- 93
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 32 · 2023: 37 · 2022: 38 · 2021: 52 · 2020: 53 · 2019: 61 · 2018: 57 · 2017: 48 · 2016: 35 · 2015: 23 · 2014: 8
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Opinion in Genetics & Development (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (098051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- mutational signatures, somatic mutations, mutational processes, cancer genomics, mutation patterns
- MeSH terms
- Humans, Mutation, Neoplasms, Genome, Human, Tumor Suppressor Protein p53, Genomics, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
